Jürgen Götz, from UQ’s Queensland Brain Institute (QBI), says the recent FDA approval of amyloid-beta antibodies for treating early-stage Alzheimer’s disease in humans is encouraging but ...

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.